Literature DB >> 31240390

Utility of Coagulation Markers for the Prediction of Rapidly Progressive Interstitial Lung Disease in Patients with Dermatomyositis.

Tomoya Sagawa1, Takashi Kida1, Tohru Inaba2, Isao Yokota3, Risa Sagawa1, Akiko Kasahara1, Shunya Kaneshita1, Takuya Inoue1, Hidetake Nagahara1, Kazuki Fujioka1, Makoto Wada1, Masataka Kohno1, Yutaka Kawahito4.   

Abstract

We aimed to evaluate the utility of coagulation markers for the prediction of rapidly progressive interstitial lung disease (RP-ILD) in patients with dermatomyositis (DM). In this retrospective study, 29 patients with DM-associated ILD were analyzed. The number of patients with RP-ILD was 15 (52%). The baseline clinical and demographic data and laboratory markers were analyzed to identify predictive factors for RP-ILD.The univariate logistic regression analysis demonstrated that in addition to well-known laboratory markers, such as serum ferritin, KL-6, and lymphocyte counts, a prolonged activated partial thromboplastin time (aPTT) ratio at the time of DM-associated ILD diagnosis was useful for predicting RP-ILD. Moreover, the logistic regression model and receiver operating characteristic curve analysis showed that combinations of the aPTT ratio and well-known laboratory markers were significantly effective in predicting RP-ILD. This study suggested that an association between RP-ILD and the coagulation system exists.

Entities:  

Keywords:  Activated partial thromboplastin time; Dermatomyositis; Interstitial lung disease; Rapidly progressive interstitial lung disease

Year:  2019        PMID: 31240390     DOI: 10.1007/s00408-019-00245-0

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  17 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody.

Authors:  Kiminobu Tanizawa; Tomohiro Handa; Ran Nakashima; Takeshi Kubo; Yuji Hosono; Kizuku Watanabe; Kensaku Aihara; Toru Oga; Kazuo Chin; Sonoko Nagai; Tsuneyo Mimori; Michiaki Mishima
Journal:  Respir Med       Date:  2011-05-31       Impact factor: 3.415

3.  Elevated serum D-dimer level is associated with an increased risk of acute exacerbation in interstitial lung disease.

Authors:  Genta Ishikawa; Samuel O Acquah; Mary Salvatore; Maria L Padilla
Journal:  Respir Med       Date:  2017-05-19       Impact factor: 3.415

Review 4.  The acute respiratory distress syndrome.

Authors:  Michael A Matthay; Lorraine B Ware; Guy A Zimmerman
Journal:  J Clin Invest       Date:  2012-08-01       Impact factor: 14.808

5.  Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis.

Authors:  Takahisa Gono; Yasushi Kawaguchi; Masako Hara; Ikuko Masuda; Yasuhiro Katsumata; Mikiko Shinozaki; Yuko Ota; Eri Ozeki; Hisashi Yamanaka
Journal:  Rheumatology (Oxford)       Date:  2010-04-12       Impact factor: 7.580

Review 6.  Coagulation Testing in the Core Laboratory.

Authors:  William E Winter; Sherri D Flax; Neil S Harris
Journal:  Lab Med       Date:  2017-11-08

7.  Anticoagulant therapy for idiopathic pulmonary fibrosis.

Authors:  Hiroshi Kubo; Katsutoshi Nakayama; Masaru Yanai; Tomoko Suzuki; Mutsuo Yamaya; Mika Watanabe; Hidetada Sasaki
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

Review 8.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.

Authors:  Harold R Collard; Christopher J Ryerson; Tamera J Corte; Gisli Jenkins; Yasuhiro Kondoh; David J Lederer; Joyce S Lee; Toby M Maher; Athol U Wells; Katerina M Antoniou; Juergen Behr; Kevin K Brown; Vincent Cottin; Kevin R Flaherty; Junya Fukuoka; David M Hansell; Takeshi Johkoh; Naftali Kaminski; Dong Soon Kim; Martin Kolb; David A Lynch; Jeffrey L Myers; Ganesh Raghu; Luca Richeldi; Hiroyuki Taniguchi; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2016-08-01       Impact factor: 21.405

9.  Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.

Authors:  Y Xu; C S Yang; Y J Li; X D Liu; J N Wang; Q Zhao; W G Xiao; P T Yang
Journal:  Clin Rheumatol       Date:  2015-12-10       Impact factor: 2.980

10.  Thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis: a proof of concept study.

Authors:  Kenji Tsushima; Koichi Yamaguchi; Yuta Kono; Toshiki Yokoyama; Keishi Kubo; Takuma Matsumura; Yasunori Ichimura; Mitsuhiro Abe; Jiro Terada; Koichiro Tatsumi
Journal:  Pulm Pharmacol Ther       Date:  2014-05-14       Impact factor: 3.410

View more
  2 in total

1.  Risk Factors and Predictive Model for Dermatomyositis Associated with Rapidly Progressive Interstitial Lung Disease.

Authors:  Kai Wang; Yian Tian; Shanshan Liu; Zhongyuan Zhang; Leilei Shen; Deqian Meng; Ju Li
Journal:  Pharmgenomics Pers Med       Date:  2022-09-01

2.  KL-6 as an Immunological Biomarker Predicts the Severity, Progression, Acute Exacerbation, and Poor Outcomes of Interstitial Lung Disease: A Systematic Review and Meta-Analysis.

Authors:  Tao Zhang; Ping Shen; Chunyan Duan; Lingyun Gao
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.